Corindus Announces First Robotic-Assisted Interventions in Japan for CorPath GRX Post-Market Study

Corindus Vascular Robotics Inc., a developer of precision vascular robotics, announced that the first clinical robotic-assisted PCI procedures in Japan were completed in partnership with Takafumi Ueno, M.D., Ph.D., director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital. These procedures mark initial enrollment in a post-market study of CorPath GRX in Japan. CorPath GRX received Pharmaceutical and Medical Device Agency (PMDA) approval in 2018 and A1 technical fee reimbursement for Japan in March of this year.
 
“The acceptance of robotic-assisted PCI in Japan is an important next step for Corindus to bring this critical medical advancement to additional markets across the globe. Japan represents one of the largest markets for PCI globally, with over 1,200 hospitals performing nearly 250,000 PCI procedures annually,” said Mark Toland, president and CEO of Corindus Vascular Robotics. “We are thrilled to have partnered with Dr. Ueno, Kurume University Hospital, and Japan Medicalnext to launch the first vascular robotic program in Japan, offering these patients the benefits of robotic-assisted PCI.”
 
This is the first CorPath GRX System placed by the company’s Japanese distribution partner, Japan Medicalnext Co. Ltd., a wholly-owned entity of MC Healthcare Inc. (a subsidiary of Mitsubishi Corporation), following the launch of a partnership in 2017.
 
“After completing the first cases with CorPath GRX, I am impressed with the capabilities of the system, including the level of precision and control during complex procedures,” stated Dr. Ueno. “Robotics will provide Japan with cutting-edge technology in interventional medicine, and we are pleased to be one of the first facilities in the Asia-Pacific region to offer this treatment to our patients.”
 
Corindus Vascular Robotics is a global technology developer of robotic-assisted vascular interventions. The company’s CorPath platform is the first U.S. Food and Drug Administration-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. The company is focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world.